#news #biotech With just $3M upfront, Sierra buys an unwanted Gilead late-stage cancer drug

09:37 EDT 22 Aug 2018 | Biotech 365

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: With just $3M upfront, Sierra buys an unwanted Gilead late-stage cancer drug .Gilead paid billions to get into the CAR-T game with its purchase of Kite Pharma, and … Continue reading

Cet article #news #biotech With just $3M upfront, Sierra buys an unwanted Gilead late-stage cancer drug est apparu en premier sur Biotech 365.

More From BioPortfolio on "#news #biotech With just $3M upfront, Sierra buys an unwanted Gilead late-stage cancer drug"